REGN · News · 20260809N

Securities Fraud Litigation

REGENERON PHARMACEUTICALS, INC. · 2026-08-09 · Importance 34 · Surprise 42

Regeneron faces securities class-action allegations concerning disclosures about failed or underperforming Phase III studies. Bronstein, Gewirtz & Grossman alleges that, between August 1, 2023, and May 15, 2024, Regeneron failed to disclose flawed preliminary statistical assumptions and limited clinical differentiation in its aflibercept study. Faruqi & Faruqi alleges misleading statements regarding the Phase III Fianlimab-Libtayo study for investors who purchased securities between August 1, 2025, and May 15, 2026, after the study failed to reach statistical significance and the stock price declined. Lead-plaintiff deadlines cited in the reports are September 14 and September 16, 2026.

Key facts

• A class action lawsuit was filed on behalf of investors who purchased Regeneron securities between August 1, 2023, and May 15, 2024. source
• Bronstein urges investors to join the case by September 16, 2026. source
• Faruqi & Faruqi, LLP reminded investors of a September 14, 2026 deadline to seek lead plaintiff status in a federal securities class action against Regeneron. source
• The Bronstein complaint alleges Regeneron made materially false and misleading statements and failed to disclose that preliminary statistical assumptions for its Phase III aflibercept study were flawed, the active treatment arm lacked meaningful clinical differentiation from standard therapies, and the study was unlikely to achieve statistical significance for its primary endpoint. source
• Faruqi & Faruqi solicits investors who purchased Regeneron securities between August 1, 2025, and May 15, 2026 to contact the firm regarding losses. source
• Regeneron faces ongoing securities litigation related to a failed Phase 3 melanoma trial. source